(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

A robust treatment plan for COPD includes a combination of prescription medication, pulmonary therapies, and healthy lifestyle changes to help relieve symptoms and slow disease progression.

For World Asthma Day, GINA released its 2025 guidelines update and joined in a campaign to make inhaled asthma therapies more ...

Mucus plugs affect some 40% to nearly 70% of COPD patients, and even clinically silent mucus plugs are linked to poorer ...

For patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations and a blood eosinophil count ...

Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 - SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

May 8, 2025 — A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...